# The Study Will Evaluate the Efficacy of AZD5423 in Patients With Mild Asthma Challenged With an Inhaled Allergen

> **NCT01225549** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 27 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** AZD5423
- **DRUG:** Budesonide 200 microgram
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01225549
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2015-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01225549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01225549, "The Study Will Evaluate the Efficacy of AZD5423 in Patients With Mild Asthma Challenged With an Inhaled Allergen". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01225549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*